1. 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES. (May 2023) Authors: Xu, Q.; Streuer, A.; Jann, J.-C.; Altrock, E.; Schmitt, N.; Flach, J.; Sens-Albert, C.; Rapp, F.; Wolf, J.; Nowak, V.; Weimer, N.; Obländer, J.; Palme, I.; Kuzina, M.; Jawhar, A.; Darwich, A.; Weis, C.-A.; Marx, A.; Wuchter, P.; Costina, V. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE. (May 2023) Authors: Schmitt, N.; Streuer, A.; Danner, J.; Altrock, E.; Riabov, V.; Xu, Q.; Rapp, F.; Weimer, N.; Palme, I.; Nowak, V.; Obländer, J.; Göl, M.; Darwich, A.; Steiner, L.; Boch, T.; Jawhar, M.; Metzgeroth, G.; Hofmann, W.-K.; Nowak, D. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS. (May 2023) Authors: Ryabov, V.; Xu, Q.; Schmitt, N.; Streuer, A.; Ge, G.; Bolanos, L.; Wunderlich, M.; Jann, J.-C.; Wein, A.; Altrock, E.; Mukherjee, S.; Ali, A.M.; Rapp, F.; Nowak, V.; Weimer, N.; Obländer, J.; Palme, I.; Göl, M.; Jawhar, A.; Darwich, A. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗